Comparison of the International Health Care Systems Through the Consideration of Population Health and Performance Indicators in Canada, Australia and New Zealand: a systematic literature review

2021 ◽  
Vol 11 (2) ◽  
pp. 199-205
Author(s):  
Nang Thet Hsu Hnin ◽  
Dr Nang Khin Mya
Keyword(s):  
Health Care ◽  
New Zealand ◽  
Literature Review ◽  
Population Health ◽  
Performance Indicators ◽  
Health Care Systems ◽  
International Health ◽  
Care Systems ◽  
And Performance ◽  
International Health Care

International Health Care Systems

2015 ◽  
Vol 372 (1) ◽  
pp. 75-76 ◽  
Author(s):  
Stephen Morrissey ◽  
David Blumenthal ◽  
Robin Osborn ◽  
Gregory D. Curfman ◽  
Debra Malina
Keyword(s):  
Health Care ◽  
Health Care Systems ◽  
International Health ◽  
Care Systems ◽  
International Health Care

International Health Care Systems: Models, Components, and Goals

2021 ◽  
pp. 1369-1387
Author(s):  
Honore Kabwebwe Mitonga ◽  
Anna Panduleni Kauko Shilunga
Keyword(s):  
Health Care ◽  
Health Care Systems ◽  
International Health ◽  
Care Systems ◽  
Systems Models ◽  
International Health Care

Handbook of International Health Care Systems

2001 ◽  
Author(s):  
Khi V. Thai ◽  
Edward T. Wimberley ◽  
Sharon M. McManus
Keyword(s):  
Health Care ◽  
Health Care Systems ◽  
International Health ◽  
Care Systems ◽  
International Health Care

scholarly journals Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review

2020 ◽  
Vol 13 (11) ◽  
pp. 400
Author(s):  
Arnold G. Vulto ◽  
Jackie Vanderpuye-Orgle ◽  
Martin van der Graaff ◽  
Steven R. A. Simoens ◽  
Lorenzo Dagna ◽  
...  
Keyword(s):  
Health Care ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Health Care Systems ◽  
Delphi Panel ◽  
The European Union ◽  
Modified Delphi ◽  
Care Systems ◽  
Supply Risks ◽  
The Impact

Introduction: Biosimilars have the potential to enhance the sustainability of evolving health care systems. A sustainable biosimilars market requires all stakeholders to balance competition and supply chain security. However, there is significant variation in the policies for pricing, procurement, and use of biosimilars in the European Union. A modified Delphi process was conducted to achieve expert consensus on biosimilar market sustainability in Europe. Methods: The priorities of 11 stakeholders were explored in three stages: a brainstorming stage supported by a systematic literature review (SLR) and key materials identified by the participants; development and review of statements derived during brainstorming; and a facilitated roundtable discussion. Results: Participants argued that a sustainable biosimilar market must deliver tangible and transparent benefits to the health care system, while meeting the needs of all stakeholders. Key drivers of biosimilar market sustainability included: (i) competition is more effective than regulation; (ii) there should be incentives to ensure industry investment in biosimilar development and innovation; (iii) procurement processes must avoid monopolies and minimize market disruption; and (iv) principles for procurement should be defined by all stakeholders. However, findings from the SLR were limited, with significant gaps on the impact of different tender models on supply risks, savings, and sustainability. Conclusions: A sustainable biosimilar market means that all stakeholders benefit from appropriate and reliable access to biological therapies. Failure to care for biosimilar market sustainability may impoverish biosimilar development and offerings, eventually leading to increased cost for health care systems and patients, with fewer resources for innovation.

Sign in / Sign up

Export Citation Format

Share Document